CDEK
← All drugs Report issue

anti-cd19/20-car vector-transduced t cells

Cell therapyexperimental

Clinical trial activity

11 trials · 8 clinical orgs · 0 marketing orgs

Phase 1
5
Phase 2
8
Phase 3
0
Phase 4
0

Earliest trial started Apr 1, 2017 (NCT03097770)

Timeline

2010s

  1. Jan 1, 2017

    Earliest Phase 1 Sponsor(trial)

2020s

  1. Jan 1, 2021

    Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • anti-cd19/20-car vector-transduced t cells
  • anti-cd19/22-car vector-transduced t cells

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07178431Phase 1/Phase 2 (Phase 2)Jan 30, 2026Humboldt University, Miltenyi Biotec, Inc.
NCT07288879Phase 2Dec 10, 2025Miltenyi Biotec, Inc.
NCT06508931Phase 2Apr 1, 2025Miltenyi Biotec, Inc.
NCT06911710Phase 1/Phase 2 (Phase 2)Nov 9, 2024Government of China, Tianjin Medical University
NCT06508775N/AMay 5, 2024Miltenyi Biotec, Inc., University of Munster
NCT04844866Phase 2Aug 18, 2021ICON, Miltenyi Biotec, Inc., University of Cologne
NCT04792489Phase 2May 25, 2021Miltenyi Biotec, Inc.
NCT03870945Phase 1/Phase 2 (Phase 2)Feb 25, 2019ICON, Miltenyi Biotec, Inc., University of Cologne
NCT03605238Phase 1Aug 15, 2018People's Liberation Army of China
NCT03185494Phase 1/Phase 2 (Phase 2)Jul 1, 2017People's Liberation Army of China
NCT03097770N/AApr 1, 2017People's Liberation Army of China
Showing 11 of 11 trials
Page 1 / 1

Organizations

Research & Development (8)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Miltenyi Biotec, Inc.For profit7722019
People's Liberation Army of ChinaGovernment3332017
ICONFor profit2012019
University of CologneAcademic/Hospital2012019
Government of ChinaGovernment1012024
Humboldt UniversityAcademic/Hospital1012026
Tianjin Medical UniversityAcademic/Hospital1112024
University of MunsterAcademic/Hospital1012024
8 organizations
Page 1 / 1